

Bevacizumab AVF2107g

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Bevacizumab AVF2107g

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Treatment of patients with metastatic carcinoma of the colon or rectum
Experimental Arm: Bevacizumab + IFL (irinotecan, leucovorin, fluorouracil)
Control Arm: IFL (irinotecan, leucovorin, fluorouracil) + placebo

